![]() | Richard James GilbertsonDepartment of Oncology, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, England; | University of Cambridge, CRUK Cambridge Institute, Li Ka Shing Centre, Robinson ... |
KOL Resume for Richard James Gilbertson
Year | |
---|---|
2022 | Department of Oncology, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, England; University of Cambridge, CRUK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK. Electronic address: |
2021 | Cancer Research UK Cambridge Centre, CRUK Cambridge Institute, Li Ka Shing Centre, Cambridge CB2 0RE, UK. Department of Oncology, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK |
2020 | Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE |
2019 | Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge CB2 0QQ, United Kingdom; email: , |
2018 | Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Cambridge, England, United Kingdom. Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge CB2 0XZ, UK |
2017 | Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA. Ingo K. Mellinghoff, Memorial Sloan Kettering Cancer Center, New York, NY; and Richard J. Gilbertson, University of Cambridge, Cambridge, United Kingdom. |
2016 | Departments of Pharmaceutical Sciences (Y.T.P., M.O.J., A.D.D., D.C.T. C.F.S.), Hematology (N.B.), and Developmental Neurobiology (R.J.G.), Preclinical Pharmacokinetic Shared Resource (P.K.V., B.B.F.), St. Jude Children's Research Hospital, Memphis, Tennessee; Merck, Rahway, New Jersey (D.C.T.); and Cambridge Cancer Centre, Cambridge, United Kingdom (R.J.G.). Cambridge Cancer Centre, Cambridge, UK |
2015 | St. Jude Children's Research Hospital, Memphis, TN, USA Giles W. Robinson, Brent A. Orr, Gang Wu, Tong Lin, Ibrahim Qaddoumi, Sue C. Kaste, Michael Rusch, Sariah J. Allen, Arzu Onar-Thomas, Clinton F. Stewart, James M. Boyett, Richard J. Gilbertson, David W. Ellison, and Amar Gajjar, St Jude Children's Research Hospital, Memphis, TN; Sridharan Gururangan and Annick Desjardins, Duke University Medical Center, Durham, NC; Roger J. Packer, Children's National Medical Center, Washington, DC; Stewart Goldman, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; Michael D. Prados, University of California San Francisco, San Francisco, CA; Murali Chintagumpala, Texas Children's Cancer Center, Houston, TX; Naoko Takebe, National Cancer Institute, Bethesda, MD; Maryam Fouladi, Cincinnati Children's Hospital, Cincinnati, OH; and Tom Curran, Children's Hospital of Philadelphia, Philadelphia, PA. Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee (K.D.W., R.J.G., A.G.); Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee (V.M.D., D.C.T., C.F.S); Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee (A.O.-T.); Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, Tennessee (N.B., R.J.G.); Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee (B.A.O.) CR UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Robinson Way, Cambridge, CB2 ORE, UK. |
2014 | Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas (L.B.K., M.C., J.S., S.M.B.); Department of Biostatistics, Operations and Biostatistics Center for Pediatric Brain Tumor Consortium, St. Jude Children's Research Hospital, Memphis, Tennessee (M.K., J.M.B.); Eli Lilly and Company, Indianapolis, Indiana (R.L.D.); Division of Neuro-oncology, St. Jude Children's Research Hospital, Memphis, Tennessee (C.W., R.G.); Ann and Robert H. Lurie Children's Hospital of Chicago, Center for Cancer and Blood Disorders, Northwestern University Feinberg School of Medicine, Chicago, Illinois (S.G.); Department of Pediatrics, Division of Hematology/Oncology, University of California San Francisco, San Francisco, California (A.B.); Department of Hematology Oncology, Cincinnati Children's Hospital Medical Center,Cincinnati, Ohio (M.F.); Department of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee (L.K.); Department of Preventive Medicine, University of Tennessee Health Science Center Memphis, Tennessee (M.K.) St Jude Children’s Research Hospital - Washington University Pediatric Cancer Genome Project, USA |
2013 | St. Jude Children's Research Hospital, Memphis, Tennessee 03105, Saint Jude Children's Research Hospital Department of Developmental Neurobiology Memphis, Tennessee |
2012 | St Jude Children’s Research Hospital - Washington University Pediatric Cancer Genome Project |
2011 | St Jude Children's Research Hospital, Memphis, TN |
Richard James Gilbertson: Influence Statistics
Concept | World rank |
---|---|
tumors provide | #1 |
trkb receptors gli1 | #1 |
subsequent 28day courses | #1 |
cancers diversity goal | #1 |
pediatric cancers studies | #1 |
demethoxygeldanamycin requires | #1 |
detrimental longterm survivors | #1 |
15 lower exposure | #1 |
origin histological classification | #1 |
cells crypt base | #1 |
medulloblastoma cells 17aag | #1 |
improvements microarray technologies | #1 |
receptor specimens | #1 |
ependymoma gene | #1 |
clofarabine disposition mice | #1 |
subgroups ependymoma | #1 |
ependymoma processes | #1 |
ecf clofarabine | #1 |
erbb2 medulloblastoma cells | #1 |
agdex similarity | #1 |
crossspecies genomics | #1 |
clofarabine 30 | #1 |
clofarabine pediatric ependymoma | #1 |
profiling humans leukemia | #1 |
tumor specimens il13ralpha2 | #1 |
anaplasia data | #1 |
tumours biological | #1 |
fusion l1cam | #1 |
ependymomas tumours | #1 |
sva exposure tecf | #1 |
evaluate agreement | #1 |
erbb2 pediatric cancer | #1 |
archer proteome | #1 |
medulloblastoma receptor | #1 |
brainstem glioma bsg | #1 |
brain tumor ependymoma | #1 |
proven guilty | #1 |
exposure sva | #1 |
refractory ependymoma | #1 |
medulloblastoma childhood brain | #1 |
genes medulloblastoma | #1 |
medulloblastoma formation knowledge | #1 |
stem ependymomas | #1 |
subtypes medulloblastoma | #1 |
c11orf95 | #1 |
prom1 stem cells | #1 |
vorinostat suspension | #1 |
collaborative ependymoma | #1 |
sensitivity medulloblastoma | #1 |
mtd 230 | #1 |
Open the FULL List in Excel | |
Prominent publications by Richard James Gilbertson
BACKGROUND: Medulloblastoma is associated with rare hereditary cancer predisposition syndromes; however, consensus medulloblastoma predisposition genes have not been defined and screening guidelines for genetic counselling and testing for paediatric patients are not available. We aimed to assess and define these genes to provide evidence for future screening guidelines.
METHODS: In this international, multicentre study, we analysed patients with medulloblastoma from retrospective cohorts ...
Known for Genetic Predisposition | Patients Medulloblastoma | Germline Mutations | Brca2 Palb2 | Highest Prevalence |
Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups
[ PUBLICATION ]
Medulloblastoma is heterogeneous, being characterized by molecular subgroups that demonstrate distinct gene expression profiles. Activation of the WNT or SHH signaling pathway characterizes two of these molecular subgroups, the former associated with low-risk disease and the latter potentially targeted by novel SHH pathway inhibitors. This manuscript reports the validation of a novel diagnostic immunohistochemical method to distinguish SHH, WNT, and non-SHH/WNT tumors and details their ...
Known for Molecular Subgroups | Wnt Shh | Proteins Signal | Immunohistochemical Markers | Factors Disease |
BACKGROUND: Young children with medulloblastoma have a poor overall survival compared with older children, due to use of radiation-sparing therapy in young children. Radiotherapy is omitted or reduced in these young patients to spare them from debilitating long-term side-effects. We aimed to estimate event-free survival and define the molecular characteristics associated with progression-free survival in young patients with medulloblastoma using a risk-stratified treatment strategy ...
Known for Young Children | Chemotherapy Patients | Adapted Therapy | Adjuvant Child | Methylation Profiling |
PURPOSE: To describe clinical features, therapeutic approaches, and prognostic factors in pediatric patients with atypical teratoid/rhabdoid tumors (ATRT) treated at St Jude Children's Research Hospital (SJCRH).
PATIENTS AND METHODS: Primary tumor samples from patients diagnosed with ATRT at SJCRH between July 1984 and June 2003 were identified. Pathology review included histologic, immunohistochemical analysis, and fluorescence in situ hybridization for SMARCB1 (also known as ...
Known for Atrt Patients | Radiation Therapy | Children 3 | Situ Hybridization | Germ Cell |
Prominin1 marks intestinal stem cells that are susceptible to neoplastic transformation
[ PUBLICATION ]
Cancer stem cells are remarkably similar to normal stem cells: both self-renew, are multipotent and express common surface markers, for example, prominin 1 (PROM1, also called CD133). What remains unclear is whether cancer stem cells are the direct progeny of mutated stem cells or more mature cells that reacquire stem cell properties during tumour formation. Answering this question will require knowledge of whether normal stem cells are susceptible to cancer-causing mutations; however, ...
Known for Stem Cells | Neoplastic Transformation | Small Intestinal | Tumour Formation | Cell Lineage |
BACKGROUND: Current treatment for medulloblastoma, which includes postoperative radiotherapy and 1 year of chemotherapy, does not cure many children with high-risk disease. We aimed to investigate the effectiveness of risk-adapted radiotherapy followed by a shortened period of dose-intense chemotherapy in children with medulloblastoma.
METHODS: After resection, patients were classified as having average-risk medulloblastoma (< or = 1.5 cm2 residual tumour and no metastatic disease) or ...
Known for Dose Chemotherapy | Medulloblastoma Patients | Risk Disease | Craniospinal Radiotherapy | Year Survival |
Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice
[ PUBLICATION ]
As a single agent the ERBB1 inhibitor, gefitinib (Iressa; ZD1839) showed minimal activity against a panel of 10 pediatric tumor xenografts that do not express the ERBB1 receptor. However, combined with irinotecan (CPT-11), significantly greater than additive activity was observed in four of eight models (P < 0.05), and the combination showed enhanced activity against three additional tumor lines. Breast cancer resistance protein (ABCG2), a transporter that confers resistance to SN-38 ...
Known for Oral Bioavailability | Antitumor Activity | Irinotecan Abcg2 | Gefitinib Enhances | Xenograft Models |
DDX3X acts as a live-or-die checkpoint in stressed cells by regulating NLRP3 inflammasome
[ PUBLICATION ]
The cellular stress response has a vital role in regulating homeostasis by modulating cell survival and death. Stress granules are cytoplasmic compartments that enable cells to survive various stressors. Defects in the assembly and disassembly of stress granules are linked to neurodegenerative diseases, aberrant antiviral responses and cancer1–5. Inflammasomes are multi-protein heteromeric complexes that sense molecular patterns that are associated with damage or intracellular pathogens, ...
Known for Stress Granules | Activation Inflammasomes | Cell Fate | Ddx3x Nlrp3 | Neurodegenerative Diseases |
PURPOSE: A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in children with recurrent malignant glioma (MG) and intrinsic brainstem glioma (BSG).
PATIENTS AND METHODS: Eligible patients received two doses of BVZ intravenously (10 mg/kg) 2 weeks apart and then BVZ plus CPT-11 every 2 weeks until progressive disease, unacceptable toxicity, or a maximum of 2 years of therapy. Correlative studies included diffusion weighted and T1 dynamic contrast-enhanced ...
Known for Monoclonal Antibodies | Brainstem Glioma | Bvz Cpt11 | Bevacizumab Irinotecan | Patients Grade |
Emerging evidence suggests that neural stem cells and brain tumors regulate their proliferation via similar pathways. In a previous study, we demonstrated that maternal embryonic leucine zipper kinase (Melk) is highly expressed in murine neural stem cells and regulates their proliferation. Here we describe how MELK expression is correlated with pathologic grade of brain tumors, and its expression levels are significantly correlated with shorter survival, particularly in younger ...
Known for Stem Cells | Brain Tumors | Melk Proliferation | Key Regulator | Maternal Embryonic |
Medulloblastoma is the most common malignant brain tumor in childhood. Molecular studies from several groups around the world demonstrated that medulloblastoma is not one disease but comprises a collection of distinct molecular subgroups. However, all these studies reported on different numbers of subgroups. The current consensus is that there are only four core subgroups, which should be termed WNT, SHH, Group 3 and Group 4. Based on this, we performed a meta-analysis of all molecular ...
Known for 4 Medulloblastomas | Molecular Subgroups | Clinical Data | Genetic Aberrations | Wnt Shh |
PURPOSE: To determine whether preradiotherapy (RT) chemotherapy would improve outcome for Chang stage M0-1 medulloblastoma when compared with RT alone. Chemotherapy comprised vincristine 1.5 mg/m2 weekly for 10 weeks and four cycles of etoposide 100 mg/m2 daily for 3 days, and carboplatin 500 mg/m2 daily for 2 days alternating with cyclophosphamide 1.5 g/m2.
PATIENTS AND METHODS: Patients aged 3 to 16 years inclusive were randomly assigned to receive 35 Gy craniospinal RT with a 20 Gy ...
Known for Efs Chemotherapy | International Society | Nonmetastatic Medulloblastoma | 3 Years | Adjuvant Child Child |
Key People For Brain Tumors
Richard James Gilbertson:Expert Impact
Concepts for whichRichard James Gilbertsonhas direct influence:Brain tumors, Stem cells, Primary cilia, Brain tumor, Molecular subgroups, Supratentorial ependymoma, Pediatric phase.
Richard James Gilbertson:KOL impact
Concepts related to the work of other authors for whichfor which Richard James Gilbertson has influence:Stem cells, Brain tumors, Gene expression, Central nervous, Primary cilia, Cell proliferation, Breast cancer.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |